BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15834542)

  • 1. [Peace-study. Coronary heart disease: additive therapy with ACE-inhibitors?].
    Böhm M
    Internist (Berl); 2005 May; 46(5):592-4. PubMed ID: 15834542
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
    Braunwald E; Domanski MJ; Fowler SE; Geller NL; Gersh BJ; Hsia J; Pfeffer MA; Rice MM; Rosenberg YD; Rouleau JL;
    N Engl J Med; 2004 Nov; 351(20):2058-68. PubMed ID: 15531767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PEACE study: limiting the role of angiotensin-converting enzyme inhibitors in stable coronary artery disease.
    Lee RT
    Curr Atheroscler Rep; 2005 May; 7(3):211-2. PubMed ID: 15811255
    [No Abstract]   [Full Text] [Related]  

  • 4. Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?
    Gupta M; Lonn EM; Verma S
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):124-5. PubMed ID: 16265450
    [No Abstract]   [Full Text] [Related]  

  • 5. ACE inhibitors in patients with vascular disease: should the PEACE trial change medical practice?
    Carey RM
    Curr Hypertens Rep; 2005 Apr; 7(2):119-20. PubMed ID: 15748535
    [No Abstract]   [Full Text] [Related]  

  • 6. ACE inhibition in secondary prevention: are the results controversial?
    Friedrich EB; Teo KK; Böhm M
    Clin Res Cardiol; 2006 Feb; 95(2):61-7. PubMed ID: 16598512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibitors for patients with vascular disease without left ventricular dysfunction--may they rest in PEACE?
    Pitt B
    N Engl J Med; 2004 Nov; 351(20):2115-7. PubMed ID: 15531768
    [No Abstract]   [Full Text] [Related]  

  • 8. ACE inhibition in stable coronary artery disease.
    Myers MG
    N Engl J Med; 2005 Mar; 352(9):937-9; author reply 937-9. PubMed ID: 15751128
    [No Abstract]   [Full Text] [Related]  

  • 9. ACE inhibitors: the impact of the EUROPA study on CAD.
    Cardiovasc J S Afr; 2003; 14(4):211-2. PubMed ID: 14619870
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using ACE inhibitors appropriately.
    Bicket DP
    Am Fam Physician; 2002 Aug; 66(3):461-8. PubMed ID: 12182524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
    Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibition in stable coronary artery disease.
    McCullough C
    N Engl J Med; 2005 Mar; 352(9):937-9; author reply 937-9. PubMed ID: 15751129
    [No Abstract]   [Full Text] [Related]  

  • 15. The landscape after PEACE: do all ACE inhibitors act in an identical way?
    Grajek S
    Curr Med Res Opin; 2006 Feb; 22(2):265-74. PubMed ID: 16466598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
    Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.